{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:03:57Z","timestamp":1778745837414,"version":"3.51.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The linkage between prolactin (PRL) and systemic lupus erythematosus (SLE) is still vague. Determination of serum levels of prolactin to reveal its role in patients with SLE is the aim of the study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a case-control study performed on 40 children with SLE and 40 age- and sex-matched controls. Cases were further subdivided according to disease activity into mild, moderate, and severe groups using the SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) score. Serum prolactin levels were assayed by ELISA (enzyme-linked immunosorbent assay).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>prolactin level was significantly higher in SLE patients (17.3\u2009\u00b1\u20096.6\u00a0\u00b5g\/L) than in controls (13.5\u2009\u00b1\u20095.3\u00a0\u00b5g\/L) (P value\u2009=\u20090.005). Although the prolactin level was highest in severe cases (19.3\u2009\u00b1\u20097.7\u00a0\u00b5g\/L), followed by moderate cases (17.0\u2009\u00b1\u20095.3\u00a0\u00b5g\/L), and lowest in mild cases (14.0\u2009\u00b1\u20096.2\u00a0\u00b5g\/L), the variance between the 3 groups was not statistically significant (P value\u2009=\u20090.212). A significant positive correlation between prolactin level and SLEDAI score was detected (r\u2009=\u20090.368) (P value\u2009=\u20090.019). Hyperprolactinemia was found in 8 patients (20%) but not in controls; 4 out of 8 patients with hyperprolactinemia (50%) showed neurological manifestations compared to only 3 out of 32 patients with a normal prolactin level (9.4%) (P value\u2009=\u20090.007).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A relationship between serum prolactin levels and juvenile SLE disease was detected. Neurological manifestations were more prevalent among SLE patients with hyperprolactinemia.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12969-023-00915-7","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T10:01:38Z","timestamp":1697796098000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Circulating prolactin level in Juvenile Systemic Lupus Erythematosus and its correlation with disease activity: a case control study"],"prefix":"10.1186","volume":"21","author":[{"given":"Hend Mehawed","family":"Soliman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5900-5274","authenticated-orcid":false,"given":"Balsam Sherif","family":"Fahmy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moataz Gamal","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman Shafik","family":"Shafie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,20]]},"reference":[{"key":"915_CR1","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1093\/rheumatology\/36.9.986","volume":"36","author":"CC Mok","year":"1997","unstructured":"Mok CC, Lau CS, Tan SC. Prolactin profile in a cohort of Chinese SLE patients. Br J Rheumatol. 1997;36:986\u20139.","journal-title":"Br J Rheumatol"},{"key":"915_CR2","unstructured":"Huang CM, Chou CT. Hyperprolactinemia in SLE. Chin Med J 59: 37\u201341."},{"key":"915_CR3","doi-asserted-by":"crossref","unstructured":"McMurray R, Keisler D, Kanuckel K, Izui S, Walker SE. (1991): Prolactin influences autoimmune disease activity in the female B\/W mouse. J. Immunol. 1997; 147:3780-7.","DOI":"10.4049\/jimmunol.147.11.3780"},{"key":"915_CR4","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S0889-857X(05)70166-6","volume":"26","author":"SE Walker","year":"2000","unstructured":"Walker SE, Jacobson JD. Roles of prolactin and gonadotrophinreleasing hormone in rheumatic Diseases. Rheum Dis Clin North Am. 2000;26:713\u201336.","journal-title":"Rheum Dis Clin North Am"},{"key":"915_CR5","unstructured":"Hochberg MC, Gravallese EM, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH. Rheumatology. Elsevier Health Sciences; 2018. 1808 p."},{"key":"915_CR6","doi-asserted-by":"publisher","unstructured":"Walker SE. Bromocriptine treatment of systemic lupus erythematosus. Lupus. 2001; 10 (10):762-8. https:\/\/doi.org\/10.1191\/096120301717165010. PMID: 11721704.","DOI":"10.1191\/096120301717165010"},{"key":"915_CR7","first-page":"2064","volume":"21","author":"R Pauzner","year":"1994","unstructured":"Pauzner R, Urowitz MB, Gladman DD, Cough JM. Prolactin in systemic Lupus Erythematosus. J Rheumatol. 1994;21:2064\u20137.","journal-title":"J Rheumatol"},{"key":"915_CR8","first-page":"629","volume":"23","author":"D Buskila","year":"1996","unstructured":"Buskila D, Lorber M, Neumann L, Flusser D, Shoenfeld Y. No correlation between prolactin levels and clinical activity in patients with systemic Lupus Erythematosus. J Rheumatol. 1996;23:629\u201332.","journal-title":"J Rheumatol"},{"key":"915_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3109\/03009749609069215","volume":"25","author":"B Ostendorf","year":"1996","unstructured":"Ostendorf B, Fischer R, Santen R, Schmitz-Linneweber B, Specker C, Scheneider M. Hyperprolactinemia in systemic Lupus Erythematosus? Scand J Rheumatol. 1996;25:97\u2013102.","journal-title":"Scand J Rheumatol"},{"key":"915_CR10","first-page":"2185","volume":"23","author":"CC Mok","year":"1996","unstructured":"Mok CC, Lau CS. Lack of association between prolactin levels and clinical activity in patients with systemic Lupus Erythematosus. J Rheumatol. 1996;23:2185\u20136.","journal-title":"J Rheumatol"},{"key":"915_CR11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1191\/096120398678920307","volume":"7","author":"JM Miranda","year":"1998","unstructured":"Miranda JM, Prieto RE, Paniagua R, et al. Clinical significance of serum and urine prolactin levels in lupus glomerulonephritis. Lupus. 1998;7:387\u201391.","journal-title":"Lupus"},{"key":"915_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/BF01452255","volume":"17","author":"LJ Jara","year":"1998","unstructured":"Jara LJ, Irigoyen L, Ortiz MJ, Zazueta B, Bravo G, Espinoza LR. Prolactin and interleukin-6 in neuropsychiatric Lupus Erythematosus. Clin Rheumatol. 1998;17:110\u201314.","journal-title":"Clin Rheumatol"},{"issue":"3S","key":"915_CR13","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.semarthrit.2019.09.009","volume":"49","author":"M Aringer","year":"2019","unstructured":"Aringer M. EULAR\/ACR classification criteria for SLE. Semin Arthritis Rheum. 2019;49(3S):S14\u20137. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.09.009. PMID: 31779843.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"915_CR14","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/art.1780350606","volume":"35","author":"C Bombardier","year":"1992","unstructured":"Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A Disease activity index for lupus patients. The Committee on Prognosis studies in SLE. Arthritis Rheum. 1992;35(6):630\u201340. https:\/\/doi.org\/10.1002\/art.1780350606. PMID: 1599520.","journal-title":"Arthritis Rheum"},{"issue":"239","key":"915_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/adc.45.239.13","volume":"45","author":"WA Marshall","year":"1970","unstructured":"Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970;45(239):13\u201323. https:\/\/doi.org\/10.1136\/adc.45.239.13. PMC 2020414. PMID 5440182.","journal-title":"Arch Dis Child"},{"issue":"2","key":"915_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4274\/jcrpe.v3i2.14","volume":"3","author":"E Eren","year":"2011","unstructured":"Eren E, Yap\u0131c\u0131 \u015e, \u00c7ak\u0131r ED, Ceylan LA, Sa\u011flam H, Tar\u0131m \u00d6. Clinical course of hyperprolactinemia in children and adolescents: a review of 21 cases. J Clin Res Pediatr Endocrinol. 2011;3(2):65\u20139. https:\/\/doi.org\/10.4274\/jcrpe.v3i2.14. Epub 2011 Jun 8. PMID: 21750634; PMCID: PMC3119443.","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"7","key":"915_CR17","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00467-009-1200-3","volume":"25","author":"B Falkner","year":"2010","unstructured":"Falkner B. Hypertension in children and adolescents: epidemiology and natural history. Pediatr Nephrol. 2010;25(7):1219\u201324. https:\/\/doi.org\/10.1007\/s00467-009-1200-3. Epub 2009 May 7. PMID: 19421783; PMCID: PMC2874036.","journal-title":"Pediatr Nephrol"},{"key":"915_CR18","doi-asserted-by":"publisher","unstructured":"Bloem M. The 2006 WHO child growth standards. BMJ. 2007; 334(7596):705-6. https:\/\/doi.org\/10.1136\/bmj.39155.658843.BE. PMID: 17413142; PMCID: PMC1847861.","DOI":"10.1136\/bmj.39155.658843.BE"},{"key":"915_CR19","doi-asserted-by":"crossref","unstructured":"Thakral A, Klein-Gitelman MS. An Update on Treatment and Management of Pediatric Systemic Lupus Erythematosus. Rheumatol Ther. 2016; 3(2):209\u2013219. doi: 10.1007\/s40744-016-0044-0. Epub 2016 Sep 30. PMID: 27747587; PMCID: PMC5127968.","DOI":"10.1007\/s40744-016-0044-0"},{"issue":"6","key":"915_CR20","doi-asserted-by":"publisher","first-page":"e22420","DOI":"10.1002\/jcla.22420","volume":"32","author":"M Garcia-Prat","year":"2018","unstructured":"Garcia-Prat M, Vila-Pijoan G, Martos Gutierrez S, Gala Yerga G, Garc\u00eda Guantes E, Mart\u00ednez-Gallo M, Mart\u00edn-Nalda A, Soler-Palac\u00edn P, Hern\u00e1ndez-Gonz\u00e1lez M. Age-specific pediatric reference ranges for immunoglobulins and complement proteins on the Optilite\u2122 automated turbidimetric analyzer. J Clin Lab Anal. 2018;32(6):e22420. Epub 2018 Mar 30. PMID: 29603375; PMCID: PMC6817213.","journal-title":"J Clin Lab Anal"},{"issue":"2","key":"915_CR21","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00296-011-2211-5","volume":"33","author":"M Karimifar","year":"2011","unstructured":"Karimifar M, Tahmasebi A, Bonakdar ZS, Purajam S. Correlation of serum prolactin levels and Disease activity in systematic Lupus Erythematosus. Rheumatol Int. 2011;33(2):511\u20136.","journal-title":"Rheumatol Int"},{"key":"915_CR22","first-page":"159","volume":"34","author":"SA Al-Bayyoumy","year":"2007","unstructured":"Al-Bayyoumy SA, Kadry YA, Mohammad MA, Ismaiel HM. Relation of serum prolactin level to systemic Lupus Erythematosus Disease activity: the effect of immunosuppressive medications. Egypt Rheumatol Rehab. 2007;34:159.","journal-title":"Egypt Rheumatol Rehab"},{"issue":"12","key":"915_CR23","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1177\/0961203317693094","volume":"26","author":"GG Song","year":"2017","unstructured":"Song GG, Lee YH. Circulating prolactin level in systemic Lupus Erythematosus and its correlation with Disease activity: a meta-analysis. Lupus. 2017;26(12):1260\u20138.","journal-title":"Lupus"},{"key":"915_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.4103\/ejdv.ejdv_32_17","volume":"38","author":"MI Soliman","year":"2018","unstructured":"Soliman MI, Esawy AM, Khashba SA. Role of prolactin in activity of systemic Lupus Erythematosus. Egypt J Dermatol Venerol. 2018;38:23\u20138.","journal-title":"Egypt J Dermatol Venerol"},{"key":"915_CR25","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.1756-185X.2008.00378.x","volume":"11","author":"M Jokar","year":"2008","unstructured":"Jokar M, Maybodi NT, Amini A, Fard MH. Prolactin and macroprolactin in patients with systemic Lupus Erythematosus. Int J Rheum Dis. 2008;11:257\u201362.","journal-title":"Int J Rheum Dis"},{"key":"915_CR26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000127219","volume":"66","author":"C Tsigos","year":"1997","unstructured":"Tsigos C, Papanicolaou DA, Defensor R, Mitsiadis CS, Kyrou I, Chrousos GP, et al. Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology. 1997;66:54\u201362.","journal-title":"Neuroendocrinology"},{"key":"915_CR27","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1191\/096120301717164994","volume":"10","author":"LJ Jara","year":"2001","unstructured":"Jara LJ, Vera-Lastra O, Miranda JM, Alcala M. Alvarez- Nemegyci J. Prolactin in human systemic Lupus Erythematosus. Lupus. 2001;10:748\u201356.","journal-title":"Lupus"},{"key":"915_CR28","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/1529-0131(200104)44:4<866::AID-ANR143>3.0.CO;2-6","volume":"44","author":"A Leanos-Miranda","year":"2001","unstructured":"Leanos-Miranda A, Chavez-Rueda KA, Blanco-Favela F. Biologic activity and plasma clearance of prolactin-IgG complex in patients with systemic Lupus Erythematosus. Arthritis Rheum. 2001;44:866\u201375.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"915_CR29","first-page":"2159","volume":"22","author":"JA Pando","year":"1995","unstructured":"Pando JA, Gourley MF, Wilder RL, Crofford LJ. Hormonal supplementation as treatment for cyclical rashes in patients with systemic Lupus Erythematosus. JRheumatol. 1995;22(1):2159\u201362.","journal-title":"JRheumatol"},{"issue":"4","key":"915_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.11648\/j.ijbecs.20210704.11","volume":"7","author":"JM Castillo","year":"2021","unstructured":"Castillo JM, S\u00e1nchez MA, M\u00e1rquez AM. Prolactin as a marker of active Disease in systemic Lupus Erythematosus. Int J Biomedical Eng Clin Sci. 2021;7(4):73\u20136. https:\/\/doi.org\/10.11648\/j.ijbecs.20210704.11.","journal-title":"Int J Biomedical Eng Clin Sci"},{"issue":"2","key":"915_CR31","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1172\/JCI200316530","volume":"111","author":"E Peeva","year":"2003","unstructured":"Peeva E, Michael D, Cleary J, Rice J, Chen X, Diamond B. Prolactin modulates the naive B cell repertoire. J Clin Invest. 2003;111(2):275\u201383.","journal-title":"J Clin Invest"},{"issue":"1","key":"915_CR32","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jneuroim.2004.11.008","volume":"160","author":"PC Carre\u00f1o","year":"2005","unstructured":"Carre\u00f1o PC, Saced\u00f3n R, Jim\u00e9nez E, Vicente A, Zapata AG. Prolactin affects both survival and differentiation of T-cell progenitors. J Neuroimmunol. 2005;160(1):135\u201345.","journal-title":"J Neuroimmunol"},{"key":"915_CR33","doi-asserted-by":"crossref","unstructured":"Saha S, Gonzalez J, Rosenfeld G, Keiser H, Peeva E. (2009): Prolactin alters the mechanisms of B cell tolerance induction. Arthritis Rheum. 2009; 60(6):1743-52.","DOI":"10.1002\/art.24500"},{"issue":"6","key":"915_CR34","first-page":"849","volume":"28","author":"MT Fojtikova","year":"2010","unstructured":"Fojtikova MT, Tomasov\u00e1 Stud\u00fdnkov\u00e1 J, Filkova M, Lacinova Z, Gatterova J, Pavelka K, et al. Elevated prolactin levels in patients with rheumatoid arthritis: association with Disease activity and structural damage. Clin Exp RheumatolIncl Supp. 2010;28(6):849.","journal-title":"Clin Exp RheumatolIncl Supp"},{"issue":"3","key":"915_CR35","first-page":"292","volume":"23","author":"J Rovensky","year":"2005","unstructured":"Rovensky J, Kvetnansky R, Radikova Z, Imrich R, Greguska O, Vigas M, et al. Hormone concentrations in synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol. 2005;23(3):292\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"915_CR36","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1172\/JCI107241","volume":"52","author":"G Tolis","year":"1993","unstructured":"Tolis G, Goldstein M, Friesen HG. Functional evaluation on prolactin secretion in patients with hypothalamic-pituitary disorders. J Clin Invest. 1993;52:783\u20138.","journal-title":"J Clin Invest"},{"key":"915_CR37","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1210\/jcem-54-5-881","volume":"54","author":"MC Stuart","year":"1984","unstructured":"Stuart MC, Underwood PA, Boscato L. A monoclonal antibody suitable for the radioimmunoassay for human prolactin. J Clin Endocrinol Metab. 1984;54:881\u20134.","journal-title":"J Clin Endocrinol Metab"},{"key":"915_CR38","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1191\/096120301717164994","volume":"10","author":"LJ Jara","year":"2001","unstructured":"Jara LJ, Vera-Lastra O, Miranda JM, Alcala. M and Alvarez-Nemegyei, J. Prolactin in human systemic Lupus Erythematosus. Lupus. 2001;10:748\u201356.","journal-title":"Lupus"},{"key":"915_CR39","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1196\/annals.1398.044","volume":"1109","author":"H Orbach","year":"2007","unstructured":"Orbach H, Zandman-Goddard G, Amital H, Barak V, Szekanecz Z, Szucs G, et al. Novel biomarkers in autoimmune Diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune Diseases. Ann NY Acad Sci. 2007;1109:385\u2013400.","journal-title":"Ann NY Acad Sci"},{"key":"915_CR40","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1191\/096120301701549688","volume":"10","author":"AM Jacobi","year":"2001","unstructured":"Jacobi AM, Rohde W, Ventz M, Riemekasten G, Burmester GR, Hiepe F. Enhanced serum prolactin (PRL) in patients with systemic Lupus Erythematosus: PRL levels are related to the Disease activity. Lupus. 2001;10:554\u201361.","journal-title":"Lupus"},{"key":"915_CR41","first-page":"19223","volume":"8","author":"X Zhu","year":"2015","unstructured":"Zhu X, Xu J, Li S, Huang W, Li F. Role of abnormal anterior pituitary hormones-growth hormone and prolactin in active systemic Lupus Erythematosus. Int J Clin Exp Med. 2015;8:19223\u201331.","journal-title":"Int J Clin Exp Med"},{"issue":"2","key":"915_CR42","first-page":"374","volume":"23","author":"A El-Garf","year":"1996","unstructured":"El-Garf A, Salah S, Shaarawy M, Zaki S, Anwer S. Prolactin hormone in juvenile systemic Lupus Erythematosus: a possible relationship to Disease activity and CNS manifestations. J Rheumatol. 1996;23(2):374\u20137. PMID: 8882050.","journal-title":"J Rheumatol"},{"issue":"6","key":"915_CR43","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/s1568-9972(02)00081-2","volume":"1","author":"O Vera-Lastra","year":"2002","unstructured":"Vera-Lastra O, Jara LJ, Espinoza LR. Prolactin and autoimmunity. Autoimmun Rev. 2002;1(6):360\u20134. https:\/\/doi.org\/10.1016\/s1568-9972(02)00081-2.","journal-title":"Autoimmun Rev"},{"key":"915_CR44","first-page":"2216","volume":"28","author":"M Pacilio","year":"2001","unstructured":"Pacilio M, Migliaresi S, Meli R, Ambrosono L, Bigliardo B, Di Carlo R. Elevated bioactive levels in systemic Lupus Erythematosus \u2014 association with Disease activity. J Rheumatol. 2001;28:2216\u201321.","journal-title":"J Rheumatol"},{"key":"915_CR45","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1191\/096120301717164994","volume":"10","author":"LJ Jara","year":"2001","unstructured":"Jara LJ, Vera-Lastra O, Miranda JM, Alcala M. Alvarez- Nemegyei J. Prolactin in human systemic Lupus Erythematosus. Lupus. 2001;10:748\u201356.","journal-title":"Lupus"},{"key":"915_CR46","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4103\/err.err_18_17","volume":"45","author":"MM Abdelaziz","year":"2018","unstructured":"Abdelaziz MM, Goma SH, Sayed SK, et al. Influence of prolactin and estrogen on Disease activity in patients with systemic Lupus Erythematosus. Egypt Rheumatol Rehabil. 2018;45:117\u201323. https:\/\/doi.org\/10.4103\/err.err_18_17.","journal-title":"Egypt Rheumatol Rehabil"},{"key":"915_CR47","first-page":"1546","volume":"28","author":"A Leanos-Miranda","year":"2001","unstructured":"Leanos-Miranda A, Pascoe-Lira D, Chavez\u2013Rueda K, Blanco-Favela F. Antiprolactin autoantibodies in systemic Lupus Erythematosus: frequency and correlation with prolactinemia and Disease activity. J Rheumatol. 2001;28:1546\u201353.","journal-title":"J Rheumatol"},{"key":"915_CR48","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/BF01452255","volume":"17","author":"LJ Jara","year":"1998","unstructured":"Jara LJ, Irigoyen L, Ortiz MJ, Zazueta B, Bravo G, Espinoza LR. Prolactin and interleukin-6 in neuropsychiatric Lupus Erythematosus. Clin Rheumatol. 1998;17:110\u20134.","journal-title":"Clin Rheumatol"},{"key":"915_CR49","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1191\/096120398678920299","volume":"7","author":"C Ferreira","year":"1998","unstructured":"Ferreira C, Paes M, Gouveia A, Ferreira E, Padua F, Fiuza T. Plasma homovanillic acid and prolactin in systemic Lupus Erythematosus. Lupus. 1998;7:383\u20136.","journal-title":"Lupus"},{"issue":"10","key":"915_CR50","first-page":"2140","volume":"30","author":"O Vera-Lastra","year":"2003","unstructured":"Vera-Lastra O, Mendez C, Jara LJ, Cisneros M, Medina G, Ariza R, Espinoza LR. Correlation of prolactin serum concentrations with clinical activity and remission in patients with systemic Lupus Erythematosus. Effect of conventional treatment. J Rheumatol. 2003;30(10):2140\u20136. PMID: 14528507.","journal-title":"J Rheumatol"},{"issue":"13","key":"915_CR51","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1177\/0961203315598016","volume":"24","author":"MA Abdel-Hafez","year":"2015","unstructured":"Abdel-Hafez MA, Abdel-Nabi H. Juvenile systemic Lupus Erythematosus: onset patterns and short-term outcome in Egyptian children, a single-center experience. Lupus. 2015;24(13):1455\u201361.","journal-title":"Lupus"},{"key":"915_CR52","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s00296-009-0888-5","volume":"29","author":"S Salah","year":"2009","unstructured":"Salah S, Lotfy HM, Sabry SM, Hamshary AE, Taher H. Systemic Lupus Erythematosus in Egyptian children. Rheumatol Int. 2009;29:1463\u20138.","journal-title":"Rheumatol Int"},{"issue":"7","key":"915_CR53","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.autrev.2010.02.008","volume":"9","author":"AV Rubtsov","year":"2010","unstructured":"Rubtsov AV, Rubtsova K, Kappler JW, Marrack P. Genetic and hormonal factors in female-biased autoimmunity. Autoimmun rev. 2010;9(7):494\u20138.","journal-title":"Autoimmun rev"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00915-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-023-00915-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00915-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T18:30:56Z","timestamp":1700591456000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-023-00915-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,20]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["915"],"URL":"https:\/\/doi.org\/10.1186\/s12969-023-00915-7","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,20]]},"assertion":[{"value":"23 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has received approval from Cairo University\u2019s Faculty of Medicine\u2019s research ethics committee (approval number: MS-59-2020; date: 29\/4\/2020).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing of interests"}}],"article-number":"128"}}